![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Apeiron_Board_148036936f.png)
Ligand Pharma to acquire Apeiron Biologics
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics...
![](/fileadmin/_processed_/csm_anacura_griet_ohmxbio_104d007f0f.jpg)
Anacura aquires Ohmx.bio
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a also...
![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
![](/fileadmin/_processed_/csm_Neuroblastom_Primary_super_close_merged_cfdf8283a7_47aac544fd.jpg)
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_Product_Award_winners_88844c23d2.png)
SLAS Europe 2024 honours products with most impact
Two companies were selected by the SLAS Europe 2024 jury from 13 applicants and six finalists as winners of this year's Product Award in Barcelona:...